DK0480950T3 - Kombinationsterapi til profylakse for og/eller behandling af godartet prostatahypertrofi - Google Patents

Kombinationsterapi til profylakse for og/eller behandling af godartet prostatahypertrofi

Info

Publication number
DK0480950T3
DK0480950T3 DK90909598T DK90909598T DK0480950T3 DK 0480950 T3 DK0480950 T3 DK 0480950T3 DK 90909598 T DK90909598 T DK 90909598T DK 90909598 T DK90909598 T DK 90909598T DK 0480950 T3 DK0480950 T3 DK 0480950T3
Authority
DK
Denmark
Prior art keywords
treatment
benign prostatic
prophylaxis
combination therapy
prostatic hypertrophy
Prior art date
Application number
DK90909598T
Other languages
Danish (da)
English (en)
Inventor
Fernand Labrie
Original Assignee
Endorecherche Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Endorecherche Inc filed Critical Endorecherche Inc
Application granted granted Critical
Publication of DK0480950T3 publication Critical patent/DK0480950T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Fertilizers (AREA)
  • Medicinal Preparation (AREA)
DK90909598T 1989-07-07 1990-07-05 Kombinationsterapi til profylakse for og/eller behandling af godartet prostatahypertrofi DK0480950T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37670089A 1989-07-07 1989-07-07
PCT/CA1990/000210 WO1991000731A1 (en) 1989-07-07 1990-07-05 Combination therapy for prophylaxis and/or treatment of benign prostatic hyperplasia

Publications (1)

Publication Number Publication Date
DK0480950T3 true DK0480950T3 (da) 1999-10-11

Family

ID=23486098

Family Applications (2)

Application Number Title Priority Date Filing Date
DK90909598T DK0480950T3 (da) 1989-07-07 1990-07-05 Kombinationsterapi til profylakse for og/eller behandling af godartet prostatahypertrofi
DK99106510T DK0943328T3 (da) 1989-07-07 1990-07-05 Kombinationsterapi til profylakse og/eller behandling af godartet prostatahyperplasi

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK99106510T DK0943328T3 (da) 1989-07-07 1990-07-05 Kombinationsterapi til profylakse og/eller behandling af godartet prostatahyperplasi

Country Status (17)

Country Link
US (1) US5817649A (de)
EP (3) EP0943328B1 (de)
JP (2) JP3332377B2 (de)
KR (1) KR920703063A (de)
AT (2) ATE177949T1 (de)
AU (2) AU643445B2 (de)
CA (1) CA2062973C (de)
DE (2) DE69033020T2 (de)
DK (2) DK0480950T3 (de)
ES (2) ES2133270T3 (de)
HU (1) HU223662B1 (de)
IE (2) IE990530A1 (de)
IL (1) IL94990A (de)
MY (1) MY106484A (de)
NZ (1) NZ234414A (de)
WO (1) WO1991000731A1 (de)
ZA (1) ZA905312B (de)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5204337A (en) * 1988-10-31 1993-04-20 Endorecherche Inc. Estrogen nucleus derivatives for use in inhibition of sex steroid activity
ES2189784T3 (es) * 1989-07-07 2003-07-16 Endorech Inc Procedimiento para el tratamiento de enfermedades relacionadas con adrogenos.
IL101245A0 (en) * 1991-03-20 1992-11-15 Merck & Co Inc Pharmaceutical compositions for the treatment of prostatic cancer
AU1893492A (en) * 1991-04-17 1992-11-17 Merck & Co., Inc. Pharmaceutical combination for the treatment of benign prostatic hyperplasia comtaining a 5 alpha-reductase inhibitor
US5175155A (en) * 1991-10-07 1992-12-29 Sterling Winthrop Inc. Win 49596-finasteride method of use and compositions
GB9506678D0 (en) * 1995-03-31 1995-05-24 Glaxo Inc Substituted 6-azacholesten-3-ones
US5780435A (en) 1995-12-15 1998-07-14 Praecis Pharmaceuticals Incorporated Methods for treating prostate cancer with LHRH-R antagonists
RU2000125533A (ru) 1998-03-11 2002-10-20 Эндорешерш, Инк. (Ca) Ингибиторы 17-бета-гидроксистероиддегидрогеназ 5 и 3 типа и способы их применения
EP1321146A3 (de) * 1998-03-11 2004-06-02 Endorecherche Inc. Typ 5 und Typ 3 17 Beta-Hydroxisteroid-Dehydrogenasehemmer und Verfahren zu ihrer Anwendung
DE19825591A1 (de) * 1998-06-09 1999-12-23 Jenapharm Gmbh Pharmazeutische Kombinationen zum Ausgleich eines Testosteron-Defizits beim Mann mit gleichzeitigem Schutz der Prostata
US6268377B1 (en) * 1998-09-28 2001-07-31 Merck & Co., Inc. Method for treating androgen-related conditions
EP1253966B1 (de) * 1999-08-13 2011-04-27 Curadis GmbH Substanzen und mittel zur positiven beeinflussung von kollagen
US6200573B1 (en) 1999-12-03 2001-03-13 Starcor Pharmaceuticals, Inc. Method of medical management for lower urinary tract symptoms and benign prostatic hyperplasia
US7001911B2 (en) * 2000-06-28 2006-02-21 Bristol-Myers Squibb Company Fused cyclic modulators of nuclear hormone receptor function
US20040077605A1 (en) 2001-06-20 2004-04-22 Salvati Mark E. Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
JP2004509072A (ja) * 2000-06-28 2004-03-25 ブリストル−マイヤーズ　スクイブ　カンパニー 選択的アンドロゲン受容体モジュレーター並びにその同定、設計及び使用方法
AU2001267904A1 (en) * 2000-06-30 2002-01-14 Chugai Seiyaku Kabushiki Kaisha Novel antiandrogenic agent
EP1854798A3 (de) 2000-09-19 2007-11-28 Bristol-Myers Squibb Company Kondensierte heterozyklische Succinimid-Verbindungen und Analoga daraus, Modulatoren der nuklearen Hormonrezeptorfunktion
US6953679B2 (en) 2000-09-19 2005-10-11 Bristol-Myers Squibb Company Method for the preparation of fused heterocyclic succinimide compounds and analogs thereof
US20040087548A1 (en) 2001-02-27 2004-05-06 Salvati Mark E. Fused cyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
AU2002259147A1 (en) 2001-05-08 2002-11-18 Schering Corporation Use of neurokinin receptor antagonists to treat androgen-dependent diseases
WO2003005889A2 (en) * 2001-07-10 2003-01-23 Ams Research Corporation Surgical kit for treating prostate tissue
US6903102B2 (en) 2001-09-06 2005-06-07 Schering Corporation 17β-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
PE20030705A1 (es) 2001-10-17 2003-08-21 Schering Corp Inhibidores de la 17beta-hidroxiesteroide deshidrogenasa tipo 3 para el tratamiento de enfermedades androgeno-dependientes
AU2002364082A1 (en) 2001-12-19 2003-07-09 Bristol-Myers Squibb Company Fused heterocyclic compounds and analogs thereof: modulators of nuclear hormone receptor function
CA2506290C (en) 2002-11-18 2012-04-24 Schering Corporation 17beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
AU2003293555A1 (en) 2002-12-17 2004-07-29 Schering Corporation 17 beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
US20060258628A1 (en) * 2004-07-20 2006-11-16 Steiner Mitchell S Compositions comprising 5-alpha reductase inhibitors, and SARMs and methods of use thereof
CN102357248A (zh) 2004-10-20 2012-02-22 恩多研究公司 单独的性甾体前体或与选择性雌激素受体调节剂联合用于防治绝经后女性的阴道疾病和病症
GB0513702D0 (en) 2005-07-04 2005-08-10 Sterix Ltd Compound
EP2099375B1 (de) 2007-01-02 2014-09-24 AquaBeam LLC Minimal invasive vorrichtungen zur behandlung von prostataerkrankungen
US9232959B2 (en) 2007-01-02 2016-01-12 Aquabeam, Llc Multi fluid tissue resection methods and devices
US12290277B2 (en) 2007-01-02 2025-05-06 Aquabeam, Llc Tissue resection with pressure sensing
US9284345B2 (en) * 2007-04-12 2016-03-15 Endorecherche, Inc. 17alpha-substituted steroids as systemic antiandrogens and selective androgen receptor modulators
GB0708376D0 (en) 2007-05-01 2007-06-06 Alligator Bioscience Ab Novel polypeptides and uses thereof
US8268806B2 (en) 2007-08-10 2012-09-18 Endorecherche, Inc. Pharmaceutical compositions
GB0722779D0 (en) 2007-11-20 2008-01-02 Sterix Ltd Compound
JP5506702B2 (ja) 2008-03-06 2014-05-28 アクアビーム エルエルシー 流体流れ内を伝達される光学エネルギーによる組織切除および焼灼
US9848904B2 (en) 2009-03-06 2017-12-26 Procept Biorobotics Corporation Tissue resection and treatment with shedding pulses
US10524822B2 (en) 2009-03-06 2020-01-07 Procept Biorobotics Corporation Image-guided eye surgery apparatus
WO2015035249A2 (en) 2013-09-06 2015-03-12 Procept Biorobotics Corporation Automated image-guided tissue resection and treatment
US20150031656A1 (en) * 2012-02-29 2015-01-29 Repros Therapeutics Inc. Combination therapy for treating androgen deficiency
CN104203078B (zh) 2012-02-29 2018-04-20 普罗赛普特生物机器人公司 自动化图像引导的组织切除和处理
BR112016031037B1 (pt) 2014-06-30 2023-02-07 Procept Biorobotics Corporation Aparelho para ablação de tecido vascular
CN107072591B (zh) 2014-09-05 2021-10-26 普罗赛普特生物机器人公司 与靶器官图像的治疗映射结合的医师控制的组织切除

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4329364A (en) * 1974-09-11 1982-05-11 Schering Corporation Antiandrogenic agents and methods for the treatment of androgen dependent disease states
US4039669A (en) * 1975-08-01 1977-08-02 Sterling Drug Inc. Composition for topical application and use thereof
US4087461A (en) * 1976-02-26 1978-05-02 The Johns Hopkins University Anti-androgenic steroids
DE2817157A1 (de) * 1978-04-17 1979-10-25 Schering Ag Verwendung von antioestrogenen und antigonadotrop wirkenden antiandrogenen zur prophylaxe und therapie der prostatahyperplasie
US4235893A (en) * 1978-05-08 1980-11-25 Brodie Angela M Ester derivatives of 4-hydroxy-4-androstene-3,17-dione and a method for inhibiting estrogen biosynthesis
FR2465486A1 (fr) * 1979-09-21 1981-03-27 Roussel Uclaf Nouvelle application utilisant la lh-rh ou des agonistes
US4474813A (en) * 1980-10-24 1984-10-02 Schering Corporation Pharmaceutical preparations comprising flutamide
DE3121152A1 (de) * 1981-05-22 1982-12-09 Schering Ag, 1000 Berlin Und 4619 Bergkamen "verwendung der kombination eines aromatase-hemmers mit einem antiandrogen zur prophylaxe und therapie der prostatahyperplasie"
DE3121153A1 (de) * 1981-05-22 1982-12-09 Schering Ag, 1000 Berlin Und 4619 Bergkamen "verwendung von aromatase-hemmern zur prophylaxe und therapie der prostatahyperplasie"
US4347363A (en) * 1981-09-17 1982-08-31 Sterling Drug Inc. Process for preparing 1,2-dihydro-6-methyl-2-oxo-5-(pyridinyl)nicotinonitriles
DE3339295A1 (de) * 1982-11-15 1984-05-17 Schering AG, 1000 Berlin und 4709 Bergkamen 4-hydroxy- und 4-acyloxy-4-androsten-3,17-dione zur verwendung bei der prophylaxe und therapie der prostatahyperplasie und diese enthaltende mittel fuer derartige verwendung
GR79447B (de) * 1982-12-31 1984-10-30 Mortimer Christopher H Dr
DE3323321A1 (de) * 1983-06-24 1985-01-03 Schering AG, 1000 Berlin und 4709 Bergkamen Prophylaxe und therapie von koronaren herzkrankheiten durch senkung des oestrogenspiegels
AU584070B2 (en) * 1983-12-12 1989-05-18 Edwin G. Kaszynski Hair growth modification
US5053403A (en) * 1984-05-11 1991-10-01 Norman Orentreich Methods for treatment of male-pattern baldness
US4684635A (en) * 1984-05-11 1987-08-04 Norman Orentreich Compositions and methods for inhibiting the action of androgens
DE3586053D1 (de) * 1984-08-02 1992-06-17 Labrie Pharmazeutische zusammensetzung fuer die kombinationstherapie von hormonabhaengigem krebs.
US4659695A (en) * 1985-02-08 1987-04-21 Fernand Labrie Method of treatment of prostate cancer
ATE43499T1 (de) * 1984-10-10 1989-06-15 Ile De France Synergistische empfaengnisverhuetende mischung.
GB8503940D0 (en) * 1985-02-15 1985-03-20 Erba Farmitalia 4-substituted androstendione derivatives
GB8505862D0 (en) * 1985-03-07 1985-04-11 Erba Farmitalia Steroidic 5alpha-reductase inhibitors
DE3607651A1 (de) * 1986-03-06 1987-09-10 Schering Ag Kombination von aromatasehemmer und testosteron-5(alpha)-reduktase-hemmer
IE60964B1 (en) * 1986-12-11 1994-09-07 Roussel Uclaf Zootechnical compositions containing a beta-adrenergic
US4888336A (en) * 1987-01-28 1989-12-19 Smithkline Beckman Corporation Steroid 5-alpha-reductase inhibitors
DE3888378T2 (de) * 1987-04-03 1994-09-29 Merck & Co Inc Behandlung von Prostatacarcinoma mit 17-beta-n-monosubstituierten-Carbamoyl-4-aza-5-alpha-Androst-1-en-3-onen.
US4895715A (en) * 1988-04-14 1990-01-23 Schering Corporation Method of treating gynecomastia

Also Published As

Publication number Publication date
IE902459A1 (en) 1991-02-13
CA2062973A1 (en) 1991-01-08
ATE177949T1 (de) 1999-04-15
US5817649A (en) 1998-10-06
IL94990A0 (en) 1991-06-10
HUT60138A (en) 1992-08-28
IE990530A1 (en) 2000-11-15
AU5217493A (en) 1994-02-10
ATE269066T1 (de) 2004-07-15
AU643445B2 (en) 1993-11-18
AU668434B2 (en) 1996-05-02
ES2222633T3 (es) 2005-02-01
DE69034148D1 (de) 2004-07-22
JPH04506798A (ja) 1992-11-26
JP3332377B2 (ja) 2002-10-07
WO1991000731A1 (en) 1991-01-24
KR920703063A (ko) 1992-12-17
AU5854590A (en) 1991-02-06
DE69034148T2 (de) 2005-06-30
EP0943328A3 (de) 1999-12-08
DE69033020T2 (de) 1999-08-05
DK0943328T3 (da) 2004-10-18
IL94990A (en) 1997-01-10
JP2001354590A (ja) 2001-12-25
DE69033020D1 (de) 1999-04-29
HU223662B1 (hu) 2004-11-29
CA2062973C (en) 2003-09-23
EP0943328A2 (de) 1999-09-22
EP0480950A1 (de) 1992-04-22
EP0857487A3 (de) 1999-12-08
ZA905312B (en) 1992-02-26
NZ234414A (en) 1999-05-28
ES2133270T3 (es) 1999-09-16
EP0943328B1 (de) 2004-06-16
MY106484A (en) 1995-05-30
HU9200047D0 (en) 1992-06-29
EP0480950B1 (de) 1999-03-24
IE990531A1 (en) 2000-11-15
EP0857487A2 (de) 1998-08-12

Similar Documents

Publication Publication Date Title
DK0943328T3 (da) Kombinationsterapi til profylakse og/eller behandling af godartet prostatahyperplasi
DK1039912T3 (da) Angiostatiske midler og præparater til behandling af GLC1A-glaukom
ATE218854T1 (de) Behandlung von herzrythmusstörungen durch hemmung einer multifunktionalen calcium/calmodulin- abhängigen protein kinase
MX9702380A (es) Nuevas carboxamidas con actividad antifungica.
NO942618L (no) Imidazolderivater og deres anvendelse som cytokin-inhibitorer
NO971889L (no) Forbindelser og sammensetninger for levering av aktive midler
SE7903186L (sv) Cerebralverksamt medel
FI931765A7 (fi) Steroidijohdannaisia eturauhasen liikakasvun käsittelyyn, niiden valmistus ja käytöt
IL101574A0 (en) Combination pharmaceutical compositions for the treatment of benign prostatic hyperplasia
SE9604348D0 (sv) Användning av hydroxyguanidiner
ES2088128T3 (es) Aminosulfonilureas inhibidoras de acat.
NO893142L (no) Fremgangsmaate for preservering av oftalmologiske opploesninger og sammensetninger for formaalet.
JPS5533497A (en) Silaasubstituted 1*44dihydropyridine derivative
NO20000519L (no) 2-acylaminopropanaminer som takykininreseptorantagonister
NO20002408L (no) 5-HT1F antagonister
IS5482A (is) Samsetning af virkum efnisþáttum sérstaklega af tetrahýdrópýridínum og asetýlkólín esterasa hindrandi miðlun til meðhöndlunar á elliglöpum á borð viðAlzheimers vitglöp
DE59101818D1 (de) Arzneimittelzubereitung, enthaltend Stigmasta-4-en-3-on sowie deren Verwendung.
NO885640D0 (no) Framgangsmaate og sammensetninger for katodisk beskyttelse.
DK0497906T3 (da) L-alfa-glycerophosphoryl-D-myo-inositol til behandling af perifere neuropatier og cerebropatier
AR014352A1 (es) Mezclas fungicidas y procedimiento para controlar hongos nocivos con dichas mezclas
EP0521080A4 (en) Synergistic compositions
DK630088D0 (da) Azelastinembonat, fremgangsmaade til fremstilling deraf og farmaceutiske praeparater med indhold af denne forbindelse som aktivt middel
IT1283124B1 (it) Forme e composizioni farmaceutiche per il trattamento dell'ipertrofia prostatica benigna
ATE82855T1 (de) 2',3'-dideoxypurinnucleosid/purinnucleosidphosphorylase-inhibitor kombinationstherapie und zusammensetzungen dafuer.
ATE101194T1 (de) Azeotropaehnliche zusammensetzungen von 1,3dichlor-1,1,2,2,3-pentafluorpropan und 2-methyl-2-propanol.